Tilting the AXIS towards therapeutic limits in renal cancer
- PMID: 22056245
- DOI: 10.1016/S0140-6736(11)61655-3
Tilting the AXIS towards therapeutic limits in renal cancer
Comment on
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.Lancet. 2011 Dec 3;378(9807):1931-9. doi: 10.1016/S0140-6736(11)61613-9. Epub 2011 Nov 4. Lancet. 2011. PMID: 22056247 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical